Leerink Partnrs Predicts Myriad Genetics Q2 Earnings

Myriad Genetics, Inc. (NASDAQ:MYGN) – Equities research analysts at Leerink Partnrs issued their Q2 2026 earnings per share estimates for shares of Myriad Genetics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings per share of ($0.02) for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Myriad Genetics’ current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics’ Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at $0.02 EPS.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The company had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. During the same quarter last year, the company posted ($0.12) EPS.

A number of other brokerages also recently commented on MYGN. Stephens reiterated an “equal weight” rating and set a $20.00 price objective on shares of Myriad Genetics in a research report on Thursday, January 16th. Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $30.00 to $21.00 in a report on Monday, December 9th. UBS Group reduced their target price on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday. Morgan Stanley reduced their target price on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. Finally, Raymond James restated an “outperform” rating and issued a $19.00 target price (down previously from $27.00) on shares of Myriad Genetics in a report on Tuesday. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $22.14.

Myriad Genetics Price Performance

Shares of NASDAQ:MYGN opened at $11.56 on Thursday. Myriad Genetics has a one year low of $9.76 and a one year high of $29.30. The stock has a fifty day moving average of $13.37 and a 200-day moving average of $19.21. The company has a market capitalization of $1.05 billion, a PE ratio of -8.89 and a beta of 1.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90.

Hedge Funds Weigh In On Myriad Genetics

Several hedge funds have recently bought and sold shares of MYGN. Vanguard Group Inc. grew its position in shares of Myriad Genetics by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 10,591,043 shares of the company’s stock valued at $145,203,000 after purchasing an additional 279,379 shares during the last quarter. State Street Corp grew its position in shares of Myriad Genetics by 8.3% in the third quarter. State Street Corp now owns 4,703,442 shares of the company’s stock valued at $128,827,000 after purchasing an additional 359,685 shares during the last quarter. Earnest Partners LLC grew its position in shares of Myriad Genetics by 0.4% in the fourth quarter. Earnest Partners LLC now owns 3,971,598 shares of the company’s stock valued at $54,451,000 after purchasing an additional 15,650 shares during the last quarter. Artisan Partners Limited Partnership grew its position in shares of Myriad Genetics by 13.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 2,766,729 shares of the company’s stock valued at $37,932,000 after purchasing an additional 336,770 shares during the last quarter. Finally, Disciplined Growth Investors Inc. MN grew its position in shares of Myriad Genetics by 21.1% in the third quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock valued at $69,226,000 after purchasing an additional 440,107 shares during the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.